Modifying immune responses to adeno-associated virus vectors by capsid engineering

De novo immune responses are considered major challenges in gene therapy. With the aim to lower innate immune responses directly in cells targeted by adeno-associated virus (AAV) vectors, we equipped the vector capsid with a peptide known to interfere with Toll-like receptor signaling. Specifically,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentler, Martin, Hardet, Romain, Ertelt, Moritz, Rudolf, Daniela, Kaniowska, Dorota, Schneider, Andreas, Vondran, Florian W.R., Schoeder, Clara T., Delphin, Marion, Lucifora, Julie, Ott, Michael, Hacker, Ulrich T., Adriouch, Sahil, Büning, Hildegard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485635/
https://www.ncbi.nlm.nih.gov/pubmed/37693943
http://dx.doi.org/10.1016/j.omtm.2023.08.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485635/
https://www.ncbi.nlm.nih.gov/pubmed/37693943
http://dx.doi.org/10.1016/j.omtm.2023.08.015

Ejemplares similares